NCT04702503

Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)

A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Adults With Stage I, II, or III Mycosis Fungoides (Cutaneous T-Cell Lymphoma, CTCL)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Moleculin Biotech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Single center, pilot study to evaluate the safety and efficacy topical administration of WP1220 in subjects with Stage I, II or III Mycosis Fungoides (CTCL)

Conditions

• Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Interventions

Type	Name	Description
DRUG	WP1220	Topical administration 2x daily for 84 consecutive days

Timeline

• Start date: 2019-03-08
• Primary completion: 2019-11-15
• Completion: 2020-11-15
• First posted: 2021-01-11
• Last updated: 2021-01-11

Locations

1 site across 1 country: Poland